查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916204

肽寡核苷酸偶聯物市場按連接類型、治療領域、給藥途徑和最終用戶分類－2026-2032年全球預測

Peptide Oligonucleotide Conjugate Market by Conjugation Type, Therapeutic Area, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胜肽-寡核苷酸偶聯物市場價值將達到 28.7 億美元，到 2026 年將成長至 30.9 億美元，到 2032 年將達到 48.6 億美元，年複合成長率為 7.78%。

關鍵市場統計數據
基準年 2025 28.7億美元
預計年份：2026年 30.9億美元
預測年份 2032 48.6億美元
複合年成長率 (%) 7.78%

胜肽-寡核苷酸偶聯物的關鍵框架：闡明科學進展、遞送挑戰和成功轉化研究的戰略要務

肽-寡核苷酸偶聯物是一種新興的治療模式，它結合了寡核苷酸藥理學的精準性和肽化學的遞送增強特性。這兩種截然不同的分子方法的整合旨在克服細胞內遞送、組織標靶化和生物分佈方面長期存在的挑戰，同時保持寡核苷酸序列特異性活性，使其能夠用於調控基因表現和剪接。胜肽設計、偶聯化學和分析方法的最新進展共同拓展了靶向調控疾病生物學的可能性，並提高了治療指數。

技術創新、不斷變化的法規和不斷提高的營運能力如何融合，正在重塑這種模式的發展路徑和商業性可行性

肽-寡核苷酸偶聯物領域正從多個維度發生變革。技術成熟與營運和監管方面的變革交織融合，創造了新的機會。胜肽工程的進步催生了富含精氨酸的雙親性性陽離子支架，這些支架能夠促進細胞內化和核內體逃逸；同時，針對葉酸受體、整合素和轉鐵蛋白受體的標靶化策略實現了組織選擇性遞送。此外，偶聯化學的改進提高了定位精度和穩定性，減少了脫靶切割，並改善了藥物動力學特性。

對 2025 年關稅如何改變整個開發平臺。

自2025年美國開始實施關稅政策調整以來，其累積影響凸顯了穩健的籌資策略和地理分散的供應鏈對胜肽-寡核苷酸偶聯物（PoN-CO）開發商的重要性。某些原料和胜肽合成中間體的課稅增加，凸顯了採購方面的挑戰，迫使贊助商和契約製造重新評估其供應商佈局和庫存策略。因此，許多機構目前優先考慮跨區域供應商的合格，加強關鍵試劑的策略性庫存緩衝，並探索近岸外包和區域叢集，以降低運輸和海關風險。

以細分市場主導的洞察，將偶聯化學、治療目標、給藥策略和最終用戶能力與轉化和商業化途徑聯繫起來

詳細的細分框架揭示了按偶聯物類型、治療領域、給藥途徑和最終用戶分類的策略重點和臨床應用前景。基於偶聯物類型，專案大致分為兩類：細胞穿透型和受體靶向型。細胞穿透型包括用於膜相互作用的兩親性支架、用於利用多聚陽離子攝取途徑的富含精氨酸的基序以及用於調節核內體運輸的大量陽離子序列。同時，受體標靶型著重於靶向葉酸受體、整合素受體和轉鐵蛋白受體的配體，以實現組織選擇性累積和受體介導的內吞作用。

美洲、歐洲、中東和非洲以及亞太地區的區域法規結構、臨床生態系統和製造地如何影響研發策略和市場准入

區域趨勢對胜肽-寡核苷酸偶聯物的臨床開發、監管反應、生產策略和商業性化有深遠影響。在美洲，完善的臨床研究網路、先進的醫保報銷體係以及眾多專業契約製造，為後期臨床試驗和商業化創造了有利環境。該地區的監管機構正積極與研發者合作，明確新型偶聯物的證據要求，從而製定結構化的臨床開發計劃並開展持續的監管對話。

優先考慮平台開發、垂直整合、夥伴關係模式和基於證據的商業化準備的策略性企業行動將加速專案進展。

活躍於胜肽-寡核苷酸偶聯物領域的公司正在採取各種策略來降低研發風險並加速臨床轉化。一些公司專注於平台化，建立模組化偶聯化學體系和標準化分析工具包，以擴展其產品線，同時減少不同專案間的技術差異。另一些公司則優先考慮垂直整合，投資建立內部胜肽合成和寡核苷酸生產能力，以控制品質、進度和成本。策略合作和授權協議仍然是許多專案的核心，與學術機構的合作可確保早期科學檢驗，而與合約開發和生產公司的合作則可擴大產能並提陞技術水平。

領導者可採取切實可行的策略重點，以加強翻譯流程、確保供應彈性，並使證據產生與監管機構和支付方的期望一致。

為了將技術進步轉化為永續的治療價值，行業領導者必須採取一系列協同努力。首先，他們必須優先考慮平台穩健性，透過標準化偶聯化學和分析方法，減少項目間的差異，並加快候選藥物的篩選。同時，他們必須投資於分子和轉化生物標記，以便早期可靠地測量標靶結合和動態反應，從而在早期臨床開發階段做出高效的「繼續/終止」決策。其次，他們應實現關鍵原料供應商關係的多元化，並評估區域生產方案以降低關稅風險和物流中斷的影響，同時探索能夠減少每劑藥物材料用量的工藝改進方法。

採用透明的混合方法研究途徑，結合專家訪談、文獻綜述和三角驗證，以提供有效的研究結果並找出證據缺口。

本執行摘要的研究結合了對相關領域專家的質性訪談，以及對同儕審查文獻、監管指南和公開計畫資料的嚴謹二次分析。主要研究包括對藥物發現化學家、轉化科學家、生產經理、臨床營運專家和監管顧問進行結構化訪談，以了解藥物發現、開發和生產過程中存在的實際限制和新興最佳實踐。這些專家的見解被用來檢驗假設，並揭示計畫從臨床前階段過渡到臨床試驗過程中出現的實際權衡取捨。

各方結論一致強調，需要製定全面的科學、營運和監管策略，才能將藥物發現方法的潛力轉化為持續的臨床和商業性成功。

胜肽-寡核苷酸偶聯物處於標靶序列療法和工程化遞送化學的交匯點，為攻克傳統療法難以治癒的疾病提供了新的途徑。胜肽設計和偶聯技術的科學進步降低了細胞內遞送的一些歷史障礙，但成功的臨床轉化將取決於平台標準化、生物標記驅動的開發策略以及對穩健生產網路的規劃投資。不斷變化的監管環境、關稅帶來的供應側考量以及區域生態系統的實力，都凸顯了整合科學、營運和商業性方面的全面規劃的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依連接類型分類的胜肽寡核苷酸綴合物市場

  • 細胞滲透性
    • 雙親性
    • 富含精胺酸
    • 陽離子
  • 受體標靶化
    • 葉酸受體
    • 整合素受體
    • 轉鐵蛋白受體

9. 依治療領域分類的胜肽寡核苷酸偶聯物市場

  • 遺傳性疾病
    • Duchenne氏肌肉失養症
    • 脊髓性肌肉萎縮症
  • 感染疾病
    • 細菌
    • 寄生蟲病
    • 病毒性疾病
  • 神經系統疾病
    • 阿茲海默症
    • 肌萎縮側索硬化症
    • 帕金森氏症
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤

10. 依給藥途徑分類的胜肽寡核苷酸偶聯物市場

  • 靜脈注射
    • Bolus注
    • 靜脈注射
  • 皮下注射
    • 自動噴射
    • 手動注射
  • 外用
    • 奶油
    • 修補

第11章 依最終用戶分類的胜肽寡核苷酸偶聯物市場

  • 生物製藥公司
    • 生技中小企業
    • 大型製藥公司
  • 醫院
    • 大學醫院
    • 社區醫院
  • 研究所
    • 私人研究機構
    • 公共研究機構
  • 專科診所
    • 神經內科診所
    • 腫瘤診所

12. 各地區肽寡核苷酸偶聯物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 胜肽寡核苷酸偶聯物市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國肽寡核苷酸偶聯物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章美國胜肽寡核苷酸偶聯物市場

第16章：中國胜肽寡核苷酸偶聯物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bachem Holding AG
  • Bio-Synthesis, Inc.
  • Danaher Corporation
  • GenScript Biotech Corporation
  • LGC Limited
  • Lonza Group AG
  • Merck KGaA
  • Panagene Inc.
  • Peptide Synthetics Ltd.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AE420CB15302

The Peptide Oligonucleotide Conjugate Market was valued at USD 2.87 billion in 2025 and is projected to grow to USD 3.09 billion in 2026, with a CAGR of 7.78%, reaching USD 4.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.87 billion
Estimated Year [2026] USD 3.09 billion
Forecast Year [2032] USD 4.86 billion
CAGR (%) 7.78%

Critical framing of peptide oligonucleotide conjugates to contextualize scientific advances, delivery challenges, and strategic imperatives for translational success

Peptide oligonucleotide conjugates represent an evolving therapeutic modality that links the precision of oligonucleotide pharmacology with the delivery-enhancing properties of peptide chemistry. This synthesis of two distinct molecular approaches aims to overcome longstanding obstacles in intracellular delivery, tissue targeting, and biodistribution while preserving the sequence-specific activity that makes oligonucleotides attractive for modulating gene expression and splicing. Over recent years, advances in peptide design, conjugation chemistries, and analytical methods have collectively expanded the possibilities for targeted modulation of disease biology with improved therapeutic indices.

As stakeholders assess opportunity and risk, understanding where scientific progress meets commercial feasibility is essential. The current landscape is defined by iterative improvements in peptide scaffolds, tighter control of conjugation sites to preserve oligonucleotide activity, and a growing appreciation for how route of administration and formulation shape clinical outcomes. This introduction sets the stage for deeper sections by framing the modality's core advantages and practical challenges, highlighting why a disciplined integration of chemistry, biology, and clinical strategy will determine which programs advance successfully from preclinical promise to durable clinical impact.

How converging technological innovations, regulatory evolution, and operational capabilities are reshaping development pathways and commercial viability for the modality

The landscape for peptide oligonucleotide conjugates is shifting along multiple axes, with technological maturation intersecting operational and regulatory change to create new windows of opportunity. Advances in peptide engineering have produced amphipathic, arginine-rich, and cationic scaffolds that enhance cellular entry and endosomal escape, while receptor-targeting strategies tuned to folate, integrin, and transferrin receptors enable tissue-selective delivery. In parallel, improvements in conjugation chemistries have increased positional precision and stability, reducing off-target cleavage and improving pharmacokinetic profiles.

Moving beyond technology, the clinical development pathway is evolving as sponsors design trials that integrate biomarker-driven endpoints and adaptive protocols to capture early signals of target engagement. Contract development and manufacturing partners are investing in platformized capabilities that accelerate scale-up and reduce analytical uncertainty. Regulatory authorities are increasingly receptive to modality-specific dialogues, prompting sponsors to adopt staged, evidence-based approaches to toxicity assessment and comparator selection. Taken together, these transformative shifts indicate that the modality is entering a phase where integrated, multidisciplinary programs will outpace isolated technical wins.

Comprehensive assessment of how 2025 tariff measures have altered supply strategies, manufacturing decisions, and program-level risk management across development pipelines

The cumulative effects of tariff policy shifts originating in the United States in 2025 have amplified the importance of resilient sourcing strategies and geographically diversified supply chains for developers of peptide oligonucleotide conjugates. Increased levies on certain raw materials and peptide synthesis intermediates have raised procurement pressure points, compelling sponsors and contract manufacturers to reassess supplier footprints and inventory strategies. As a result, many organizations now emphasize supplier qualification across multiple geographies, bolster strategic inventory buffers for critical reagents, and explore nearshoring or regional clustering to mitigate transit and tariff exposure.

Importantly, the tariff environment has also influenced capital allocation decisions for manufacturing capacity and process optimization. In response, some developers prioritize process intensification and yield improvements that reduce per-dose material requirements, while others seek long-term supply contracts that stabilize input costs. Clinically, the cumulative policy impact has led teams to weigh the tradeoffs between centralized manufacturing with economies of scale and distributed production that reduces tariff-related risk. Given these dynamics, leadership teams are increasingly integrating tariff scenario planning into program-level budgets and partnership negotiations to preserve timelines and maintain competitiveness.

Segment-driven insights that map conjugation chemistries, therapeutic ambitions, administration strategies, and end-user capabilities to translational and commercial pathways

A nuanced segmentation framework illuminates strategic priorities and clinical applicability across conjugation types, therapeutic areas, administration routes, and end users. Based on conjugation type, programs fall into two broad approaches: cell penetrating constructs and receptor targeting constructs. The cell penetrating axis encompasses amphipathic scaffolds designed for membrane interaction, arginine-rich motifs that leverage polycationic uptake pathways, and broader cationic sequences tuned for endosomal translocation; conversely, the receptor targeting axis emphasizes ligands directed at folate receptors, integrin receptors, and transferrin receptors to achieve tissue-selective accumulation and receptor-mediated internalization.

In terms of therapeutic area, development efforts span genetic disorders, infectious diseases, neurological conditions, and oncology. Genetic disorder programs include archetypal targets such as Duchenne muscular dystrophy and spinal muscular atrophy, which demand precise exon-skipping or splicing modulation. Infectious disease initiatives address bacterial, parasitic, and viral targets that benefit from sequence-specific inhibition strategies. Neurological disorder portfolios focus on Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease, each presenting unique central nervous system delivery and biomarker challenges. Oncology projects differentiate between hematological malignancies and solid tumors, with distinct biodistribution and microenvironmental considerations.

Route of administration further segments programs into intravenous, subcutaneous, and topical strategies. Intravenous approaches include bolus injection and infusion paradigms that support systemic exposure and rapid target engagement, while subcutaneous delivery comprises auto-injection and manual injection formats favoring outpatient and chronic use. Topical modalities span creams and patch applications that facilitate localized exposure and potentially reduce systemic exposure. Finally, end users comprise biopharmaceutical companies, hospitals, research institutes, and specialist clinics. Biopharmaceutical companies divide into biotech small and medium enterprises and large pharmaceutical firms with differing risk appetites and resource profiles. Hospitals break down into academic and community settings that influence trial design and adoption pathways. Research institutes include private laboratories and public research entities that drive basic science, and specialist clinics such as neurology and oncology centers that play a pivotal role in early clinical translation and adoption.

How regional regulatory frameworks, clinical ecosystems, and manufacturing footprints across the Americas, Europe Middle East & Africa, and Asia-Pacific shape development strategy and access

Regional dynamics exert a profound influence on clinical development, regulatory navigation, manufacturing strategy, and commercial access for peptide oligonucleotide conjugates. In the Americas, established clinical research networks, advanced reimbursement environments, and a concentration of specialized contract manufacturing organizations create a conducive ecosystem for late-stage trials and commercialization. Regulatory authorities in the region are actively engaging with developers to clarify evidence expectations for novel conjugates, which enables more structured clinical development plans and iterative regulatory interactions.

In Europe, Middle East & Africa, the regulatory landscape is heterogeneous, with varied health technology assessment processes and payer expectations that shape evidence generation and launch sequencing. Strategic partnerships with regional clinical centers and localized manufacturing can accelerate uptake by aligning dossiers with diverse regulatory and reimbursement pathways. Finally, Asia-Pacific presents a mix of strong manufacturing capacity, rapidly expanding clinical trial infrastructure, and policy environments increasingly supportive of biotechnology innovation. Regional strategies that align supply chain decisions, clinical site selection, and regulatory engagement with local capabilities can materially reduce development friction and foster more predictable program outcomes.

Strategic company behaviors that prioritize platform development, vertical integration, partnership models, and evidence-driven commercialization readiness to accelerate program advancement

Companies active in the peptide oligonucleotide conjugate space are pursuing a range of strategies to de-risk development and accelerate clinical translation. Some organizations are concentrating on platformization, building modular conjugation chemistries and standardized analytical toolkits that enable pipeline expansion while limiting technical variability across programs. Others prioritize vertical integration, investing in in-house peptide synthesis and oligonucleotide manufacturing capabilities to control quality, timelines, and cost drivers. Strategic partnerships and licensing deals remain central to many programs: alliances with academic centers secure early scientific validation, while collaborations with contract developers and manufacturers expand capacity and technical know-how.

Intellectual property management and freedom-to-operate considerations are increasingly consequential, prompting firms to adopt layered protection strategies that cover sequence design, conjugation linkers, and manufacturing processes. Clinical strategy differentiation emerges through careful selection of biomarkers, patient populations, and administration routes that match the conjugate's pharmacology. Finally, firms are enhancing commercialization readiness by engaging early with payers and health technology assessment bodies to define evidence generation plans that address long-term outcomes and comparative effectiveness, thereby smoothing the path from regulatory approval to clinical adoption.

Actionable strategic priorities for leaders to strengthen translational pipelines, secure supply resilience, and align evidence generation with regulatory and payer expectations

Industry leaders must adopt a coordinated set of actions to translate technological progress into sustainable therapeutic value. First, prioritize platform robustness by standardizing conjugation chemistries and analytical methods, thereby reducing program-to-program variability and accelerating candidate selection. Concurrently, invest in molecular and translational biomarkers that provide early, robust readouts of target engagement and pharmacodynamic response, which will enable more efficient go/no-go decisions during early clinical development. Next, diversify supplier relationships for critical raw materials and evaluate regional manufacturing options to mitigate tariff exposure and logistics disruptions, while also exploring process improvements that lower material intensity per dose.

Leaders should also pursue pragmatic regulatory engagement strategies that clarify nonclinical safety expectations specific to peptide-oligonucleotide conjugates and negotiate iterative evidence generation timelines. Form strategic alliances that combine discovery-stage agility with manufacturing scale; such collaborations can speed time to the clinic and expand capability sets. Finally, embed commercial considerations early by engaging payers and clinical thought leaders to shape value dossiers and adoption models. By aligning scientific, operational, regulatory, and commercial levers, organizations will be better positioned to advance therapeutics that meet clinical needs and achieve durable uptake.

Transparent mixed-methods research approach that integrates expert interviews, literature synthesis, and triangulation to deliver defensible insights and identified evidence gaps

The research underpinning this executive summary combines primary qualitative engagement with domain experts and rigorous secondary analysis of peer-reviewed literature, regulatory guidance, and publicly disclosed program-level data. Primary research included structured interviews with medicinal chemists, translational scientists, manufacturing leads, clinical operations experts, and regulatory advisors to capture real-world constraints and emerging best practices across discovery, development, and manufacturing stages. These expert inputs were used to validate hypotheses and illuminate practical tradeoffs that arise during program escalation from preclinical work to clinical testing.

Secondary research involved systematic review of scientific publications, conference proceedings, and regulatory documentation to map technological trends and safety considerations specific to peptide oligonucleotide conjugates. Insights were triangulated through cross-validation between primary inputs and the literature, and methodological rigor was ensured by documenting assumptions, noting evidence limitations, and highlighting areas where data remain sparse. Where appropriate, scenario analysis was applied to explore operational contingencies such as supply chain disruptions and regulatory pathways, while preserving clarity about where empirical evidence ends and expert judgment begins.

Convergent conclusions emphasizing the need for integrated scientific, operational, and regulatory strategies to convert modality promise into durable clinical and commercial outcomes

Peptide oligonucleotide conjugates occupy a promising intersection of targeted sequence-based therapeutics and engineered delivery chemistries, offering a pathway to address diseases that have been refractory to conventional approaches. Scientific progress in peptide design and conjugation has reduced several historical barriers to intracellular delivery, yet translational success will depend on deliberate investments in platform standardization, biomarker-enabled development strategies, and resilient manufacturing networks. The intersection of regulatory evolution, tariff-driven supply considerations, and regional ecosystem strengths underscores the importance of holistic planning that integrates scientific, operational, and commercial dimensions.

Moving forward, decision-makers should focus on building reproducible, scalable processes and fostering partnerships that combine discovery innovation with manufacturing and clinical execution capacity. By aligning early translational priorities with regulatory and payer expectations, organizations can enhance the probability that high-potential programs realize clinical impact. Finally, sustained dialog among scientists, clinicians, manufacturers, and policymakers will be essential to navigate the remaining technical and policy uncertainties and to accelerate the delivery of meaningful therapies to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptide Oligonucleotide Conjugate Market, by Conjugation Type

  • 8.1. Cell Penetrating
    • 8.1.1. Amphipathic
    • 8.1.2. Arginine Rich
    • 8.1.3. Cationic
  • 8.2. Receptor Targeting
    • 8.2.1. Folate Receptor
    • 8.2.2. Integrin Receptor
    • 8.2.3. Transferrin Receptor

9. Peptide Oligonucleotide Conjugate Market, by Therapeutic Area

  • 9.1. Genetic Disorders
    • 9.1.1. Duchenne Muscular Dystrophy
    • 9.1.2. Spinal Muscular Atrophy
  • 9.2. Infectious Diseases
    • 9.2.1. Bacterial
    • 9.2.2. Parasitic
    • 9.2.3. Viral
  • 9.3. Neurological Disorders
    • 9.3.1. Alzheimer's Disease
    • 9.3.2. Amyotrophic Lateral Sclerosis
    • 9.3.3. Parkinson's Disease
  • 9.4. Oncology
    • 9.4.1. Hematological Malignancies
    • 9.4.2. Solid Tumors

10. Peptide Oligonucleotide Conjugate Market, by Route Of Administration

  • 10.1. Intravenous
    • 10.1.1. Bolus Injection
    • 10.1.2. Infusion
  • 10.2. Subcutaneous
    • 10.2.1. Auto Injection
    • 10.2.2. Manual Injection
  • 10.3. Topical
    • 10.3.1. Cream
    • 10.3.2. Patch

11. Peptide Oligonucleotide Conjugate Market, by End User

  • 11.1. Biopharmaceutical Companies
    • 11.1.1. Biotech Smes
    • 11.1.2. Large Pharma
  • 11.2. Hospitals
    • 11.2.1. Academic Hospitals
    • 11.2.2. Community Hospitals
  • 11.3. Research Institutes
    • 11.3.1. Private Labs
    • 11.3.2. Public Research Institutes
  • 11.4. Specialist Clinics
    • 11.4.1. Neurology Clinics
    • 11.4.2. Oncology Clinics

12. Peptide Oligonucleotide Conjugate Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Peptide Oligonucleotide Conjugate Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Peptide Oligonucleotide Conjugate Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Peptide Oligonucleotide Conjugate Market

16. China Peptide Oligonucleotide Conjugate Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bachem Holding AG
  • 17.6. Bio-Synthesis, Inc.
  • 17.7. Danaher Corporation
  • 17.8. GenScript Biotech Corporation
  • 17.9. LGC Limited
  • 17.10. Lonza Group AG
  • 17.11. Merck KGaA
  • 17.12. Panagene Inc.
  • 17.13. Peptide Synthetics Ltd.
  • 17.14. QIAGEN N.V.
  • 17.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMPHIPATHIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMPHIPATHIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMPHIPATHIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ARGININE RICH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ARGININE RICH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ARGININE RICH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CATIONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CATIONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CATIONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY FOLATE RECEPTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY FOLATE RECEPTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY FOLATE RECEPTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTEGRIN RECEPTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTEGRIN RECEPTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTEGRIN RECEPTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TRANSFERRIN RECEPTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TRANSFERRIN RECEPTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TRANSFERRIN RECEPTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BOLUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BOLUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AUTO INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AUTO INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AUTO INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY MANUAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY MANUAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY MANUAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOTECH SMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOTECH SMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOTECH SMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PRIVATE LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PRIVATE LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, B